Nimodipine is a Ca channel blocker that inhibits smooth muscle contraction by preventing Ca from entering cells, thereby relieving vasospasm. It is highly lipophilic and easily penetrates the blood-brain barrier. It can be used to prevent vasospasm after subarachnoid hemorrhage. It also protects and promotes memory and intellectual recovery. It can selectively dilate cerebral blood vessels, increase cerebral blood flow, and reduce ischemic brain damage.

This product is a non-steroidal anti-inflammatory drug with anti-inflammatory, antipyretic and analgesic effects. Its mechanism of action is to reduce the synthesis of prostaglandins by inhibiting cyclooxygenase. It stops the formation of pain nerve impulses in inflammatory tissues and inhibits inflammatory reactions, including inhibiting the chemotaxis of leukocytes and the release of lysosomal enzymes. As for the antipyretic effect, it acts on the hypothalamic temperature regulation center, causing peripheral vasodilation and sweating, which increases heat dissipation. This central antipyretic effect may also be related to the inhibition of prostaglandin synthesis in the hypothalamus.

This product is a piperazine calcium channel antagonist that can block calcium influx into vascular smooth muscle, causing vasodilation and improving cerebral and coronary circulation, especially having a certain selective effect on cerebral blood vessels. This product can inhibit phosphodiesterase, prevent cAMP from decomposing into inactive 5-AMP, thereby increasing the intracellular cAMP concentration, inhibiting the release of histamine, 5-hydroxytryptamine, bradykinin and other biologically active substances, and also inhibiting the activation of complement C4.